Skip to main content

Cardiovascular Disease

40
Pipeline Programs
30
Companies
50
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
20
1
2
0
9
8
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
343%
Peptide
229%
Small Molecule
114%
Vaccine
114%
+ 88 programs with unclassified modality

Competitive Landscape

41 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
12 programs
7
1
2
1
AspirinPhase 41 trial
AZD0780Phase 32 trials
AZD0780Phase 31 trial
ticagrelorPhase 21 trial
14C]AZD4831 Oral SolutionPhase 1
+7 more programs
Active Trials
NCT00970918Completed2,609Est. Aug 2010
NCT04588727Completed103Est. Jan 2022
NCT03136991Completed38Est. Nov 2017
+7 more trials
ViiV Healthcare
ViiV HealthcareNC - Durham
10 programs
4
2
FLOLAN injection with currently marketed diluentPhase 4
Recombinant Herpes Zoster VaccinePhase 4Vaccine
Candesartan Cilexetil in formulation 1Phase 1
Clop F1Phase 1
GSK2212836Phase 1
+5 more programs
Angeles Therapeutics
1
PropranololPhase 4Small Molecule1 trial
Blood Draw of up to 10 mlN/A1 trial
The Miami Heart Study at Baptist Health South FloridaN/A1 trial
Active Trials
NCT02109575Completed540Est. Mar 2020
NCT02508454Active Not Recruiting4,000Est. Sep 2028
NCT06263452Recruiting120Est. May 2026
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
3 programs
1
EvolocumabPhase 4Monoclonal Antibody1 trial
CVD risk reduction programN/A1 trial
academic detailingN/A1 trial
Active Trials
NCT00829491Completed340Est. Jun 2010
NCT01247454Completed7,000Est. Sep 2010
NCT05284747Active Not Recruiting6,019Est. May 2027
Abbott
AbbottABBOTT PARK, IL
3 programs
1
ParicalcitolPhase 41 trial
Clinical Performance Evaluation of the Cholestech LDX Cardiac hsCRP Test (CLEAR)N/A1 trial
discharge vs. overnight stayN/A1 trial
Active Trials
NCT00933764Withdrawn0Est. Nov 2009
NCT01230606Completed303Est. Jun 2010
NCT01331317Completed48Est. Apr 2012
Pfizer
PfizerNEW YORK, NY
3 programs
2
1
Cocoa extractPhase 41 trial
bococizumabPhase 3Monoclonal Antibody1 trial
bococizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT01975389Terminated10,564Est. Apr 2017
NCT01975376Terminated16,784Est. Mar 2017
NCT02422745Completed21,442Est. Jun 2023
Boston Scientific
1
TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent SystemPhase 41 trial
Active Trials
NCT00569751Completed5,016Est. Jul 2008
Sharp Therapeutics
1
2
ER niacin/laropiprantPhase 31 trial
Simvastatin 20 mg dailyPhase 31 trial
INS50589 Intravenous InfusionPhase 11 trial
Active Trials
NCT00099450Completed48Est. Mar 2005
NCT00461630Completed25,673Est. Oct 2012
NCT00124072Completed12,064Est. May 2008
MSD
MSDIreland - Ballydine
3 programs
1
2
ER niacin/laropiprantPhase 3
Simvastatin 20 mg dailyPhase 3
INS50589 Intravenous InfusionPhase 1
Prevail Therapeutics
1
1
DulaglutidePhase 3Peptide1 trial
EvacetrapibPhase 11 trial
Active Trials
NCT01825889Completed20Est. Oct 2013
NCT01394952Completed9,901Est. Aug 2018
Sarepta Therapeutics
1 program
1
AVI-5126Phase 21 trial
Active Trials
NCT00451256Terminated600Est. Mar 2009
Alliance Pharmaceuticals
1 program
1
ResAPhase 1/21 trial
Active Trials
NCT01564381Completed64Est. Mar 2015
Oregon Therapeutics
1
FEIBAPhase 11 trial
CoachingN/A1 trial
Insurance InterventionN/A1 trial
Time to Talk CARDIO websiteN/A1 trial
Active Trials
NCT02839382Completed209Est. May 2018
NCT02355132Completed308,283Est. Mar 2016
NCT00983333Completed105Est. Dec 2009
+1 more trials
Quotient Therapeutics
Quotient TherapeuticsMA - Cambridge
3 programs
3
14C]AZD4831 Oral SolutionPhase 11 trial
AZD9977 capsule 50 mgPhase 11 trial
[14C]AZD5718 Oral SuspensionPhase 11 trial
Active Trials
NCT04407091Completed8Est. Aug 2020
NCT04686591Completed8Est. Feb 2021
NCT03948451Completed6Est. Jul 2019
Chong Kun Dang Pharmaceutical
2
CKD-330 Tab. and D086 Tab.Phase 11 trial
CKD-330 Tab. and D090 Tab.Phase 11 trial
Active Trials
NCT04478097Unknown51Est. Jan 2021
NCT04611932Unknown51Est. Apr 2021
GSK
GSKLONDON, United Kingdom
8 programs
EpoprostenolN/A1 trial
Fondaparinux SodiumN/A1 trial
Fondaparinux SodiumN/A1 trial
Candesartan Cilexetil in formulation 1PHASE_11 trial
Clop F1PHASE_11 trial
+3 more programs
Active Trials
NCT01387191Completed748Est. Jul 2009
NCT01390883Completed475Est. Oct 2013
NCT01390896Completed329Est. Jan 2013
+5 more trials
Human BioSciences
Cranberry juiceN/A1 trial
Lifestyle behavior change programN/A1 trial
PHVON/A1 trial
Sodium ChlorideN/A
Soybean oilN/A1 trial
+1 more programs
Active Trials
NCT01295684Completed60Est. Dec 2010
NCT00288327Completed258Est. Jan 2005
NCT00942656Completed120Est. Sep 2009
+2 more trials
Innovation Pharmaceuticals
2 programs
Characteristics of Plant Sterols Consumers in FranceN/A1 trial
Effects of trout on CVD risk markers and plasma proteomeN/A1 trial
Active Trials
NCT01629238Completed780Est. Apr 2012
NCT00445614Completed72Est. Dec 2007
City Therapeutics
City TherapeuticsMA - Cambridge
2 programs
PATHwayN/A1 trial
chocolate consumption levelN/A
Active Trials
NCT02717806CompletedEst. Jul 2018
Parexel
ParexelMA - Boston
2 programs
AZD4831PHASE_1
MidazolamPHASE_1
Elutia
ElutiaSILVER SPRING, MD
1 program
A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) EnvelopeN/A1 trial
Active Trials
NCT02530970Completed1,025Est. Apr 2018
Vantive
VantiveIL - Deerfield
1 program
HCO 1100N/A1 trial
Active Trials
NCT01363921Terminated10Est. Sep 2013
Baxter
BaxterCosta Rica - Cartago
1 program
HCO 1100N/A
Baxter International
1 program
HCO 1100N/A
Nordic Pharma
1 program
Health promotion programN/A1 trial
Active Trials
NCT01629654Completed41Est. Jun 2012
Philips
PhilipsNetherlands - Amsterdam
1 program
Low-dose DSAN/A1 trial
Active Trials
NCT01599741Completed51Est. May 2013
Nonin
1 program
Model 7600 Regional Oximeter SystemN/A1 trial
Active Trials
NCT00939224Completed100Est. Aug 2011
LivaNova
LivaNovaUK - London
1 program
Quality improvement interventionN/A1 trial
Active Trials
NCT00432536Completed469Est. Feb 2012
RenalGuard Solutions
RenalGuardN/A1 trial
Active Trials
NCT02793661Unknown300Est. May 2018
Genome & Company
Sodium ChlorideN/A1 trial
Active Trials
NCT04717336Completed36Est. Jul 2022

+11 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Angeles TherapeuticsPropranolol
Colorado TherapeuticsEvolocumab
GSKFLOLAN injection with currently marketed diluent
AstraZenecaAspirin
PfizerCocoa extract
EisaiLorcaserin hydrochloride
AbbottParicalcitol
Lantheus Medical ImagingDEFINITY®
Boston ScientificTAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System
AstraZenecaAZD0780
AstraZenecaAZD0780
Novo NordiskCagrilintide
Pfizerbococizumab
Pfizerbococizumab
Prevail TherapeuticsDulaglutide

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 167,559 patients across 50 trials

Beta-Blocker Influences on Inflammatory and Neural Responses to Stress

Start: May 2024Est. completion: May 2026120 patients
Phase 4Recruiting

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Start: Oct 2022Est. completion: May 20276,019 patients
Phase 4Active Not Recruiting
NCT02705807GSKFLOLAN injection with currently marketed diluent

Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects

Start: May 2016Est. completion: Jul 201610 patients
Phase 4Completed

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

Start: Jul 2015Est. completion: Jul 20199,006 patients
Phase 4Completed
NCT02422745PfizerCocoa extract

COcoa Supplement and Multivitamin Outcomes Study

Start: Jun 2015Est. completion: Jun 202321,442 patients
Phase 4Completed
NCT02019264EisaiLorcaserin hydrochloride

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Start: Jan 2014Est. completion: May 201814,673 patients
Phase 4Completed
NCT01331317AbbottParicalcitol

Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy

Start: Apr 2010Est. completion: Apr 201248 patients
Phase 4Completed

A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice

Start: Feb 2008Est. completion: Jul 20091,060 patients
Phase 4Completed
NCT00569751Boston ScientificTAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System

TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program

Start: Oct 2004Est. completion: Jul 20085,016 patients
Phase 4Completed

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

Start: Jun 2025Est. completion: Oct 202915,100 patients
Phase 3Recruiting

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

Start: May 2025Est. completion: Jan 20273,046 patients
Phase 3Active Not Recruiting

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Start: Mar 2023Est. completion: Oct 20277,101 patients
Phase 3Active Not Recruiting

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Start: Oct 2013Est. completion: Mar 201716,784 patients
Phase 3Terminated

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Start: Oct 2013Est. completion: Apr 201710,564 patients
Phase 3Terminated

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Start: Jul 2011Est. completion: Aug 20189,901 patients
Phase 3Completed
NCT00461630Sharp TherapeuticsER niacin/laropiprant

Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE

Start: Jan 2007Est. completion: Oct 201225,673 patients
Phase 3Completed
NCT00124072Sharp TherapeuticsSimvastatin 20 mg daily

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine

Start: Jul 1998Est. completion: May 200812,064 patients
Phase 3Completed

Ticagrelor vs. Prasugrel Effects on Infarct Size

Start: Feb 2016Est. completion: Nov 20170
Phase 2Withdrawn

Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)

Start: Mar 2007Est. completion: Mar 2009600 patients
Phase 2Terminated
NCT00839774Pulse BiosciencesWhole yellow pea flour

Effect of Pulse Fractions on Indices on Cardiovascular Disease and Diabetes Risk Factors

Start: Feb 2007Est. completion: Mar 2008
Phase 2Completed

Effects of Resveratrol Supplements on Vascular Health in Postmenopausal Women

Start: Mar 2012Est. completion: Mar 201564 patients
Phase 1/2Completed

Safety and Feasibility of the Injectable BL-1040 Implant

Start: Mar 2008Est. completion: Jan 201430 patients
Phase 1/2Unknown

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults

Start: Apr 2026Est. completion: Jul 202632 patients
Phase 1Recruiting

Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects

Start: Dec 2020Est. completion: Feb 20218 patients
Phase 1Completed

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers

Start: Nov 2020Est. completion: Apr 202151 patients
Phase 1Unknown

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

Start: Oct 2020Est. completion: Jan 2022103 patients
Phase 1Completed

A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects

Start: Jul 2020Est. completion: Oct 202014 patients
Phase 1Completed

Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

Start: Jul 2020Est. completion: Jan 202151 patients
Phase 1Unknown
NCT04407091Quotient Therapeutics14C]AZD4831 Oral Solution

A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831

Start: Jun 2020Est. completion: Aug 20208 patients
Phase 1Completed
NCT03948451Quotient Therapeutics[14C]AZD5718 Oral Suspension

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Start: Apr 2019Est. completion: Jul 20196 patients
Phase 1Completed
NCT03489005BialBIA 5-1058

Effect of BIA 5 1058 on Cardiac Repolarization

Start: Apr 2018Est. completion: Oct 201849 patients
Phase 1Completed

A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease

Start: May 2017Est. completion: Nov 201738 patients
Phase 1Completed

A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects

Start: Jun 2016Est. completion: Oct 2016104 patients
Phase 1Terminated

FEIBA and Use of Blood Products in Cardiac Surgery

Start: Feb 2016Est. completion: Mar 202012 patients
Phase 1Completed

Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects

Start: Sep 2015Est. completion: Sep 201518 patients
Phase 1Completed
NCT02254447GSKCandesartan Cilexetil in formulation 1

Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions

Start: Dec 2014Est. completion: Jan 201518 patients
Phase 1Completed

A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants

Start: Apr 2013Est. completion: Oct 201320 patients
Phase 1Completed
NCT01039961GSKlosmapimod 1 mg

PK Study of IV Formulation of GW856553

Start: Feb 2010Est. completion: Apr 201016 patients
Phase 1Completed
NCT00996268GSKGSK2212836

An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.

Start: Oct 2009Est. completion: Jan 201046 patients
Phase 1Completed
NCT00099450Sharp TherapeuticsINS50589 Intravenous Infusion

Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers

Start: Dec 2004Est. completion: Mar 200548 patients
Phase 1Completed

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African Americans Study (GENE-FORECAST): Sodium Intervention Trial (SIT)

Start: Jan 2021Est. completion: Jul 202236 patients
N/ACompleted

Technology-enabled Cardiac Rehabilitation Through PATHway. Feasibility, Clinical Effectiveness and Cost-effectiveness

Start: Jun 2017Est. completion: Jul 2018
N/ACompleted
NCT02501746Purdue PharmaUsual Clinical Care

Bridging Income Generation With Group Integrated Care

Start: Feb 2017Est. completion: Dec 20192,890 patients
N/ACompleted

Study to Evaluate the Use of RenalGuard to Protect Patients at High Risk of AKI

Start: May 2016Est. completion: May 2018300 patients
N/AUnknown
NCT02530970ElutiaA Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope

A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope

Start: Oct 2015Est. completion: Apr 20181,025 patients
N/ACompleted

The Northwest Coalition for Primary Care Practice Support

Start: May 2015Est. completion: May 2018209 patients
N/ACompleted
NCT02508454Angeles TherapeuticsThe Miami Heart Study at Baptist Health South Florida

The Miami Heart Study at Baptist Health South Florida

Start: May 2015Est. completion: Sep 20284,000 patients
N/AActive Not Recruiting

The Use of Texting Messaging to Improve the Hospital-to-community Transition Period in Cardiovascular Disease Patients

Start: Apr 2015Est. completion: Jan 201776 patients
N/ACompleted

Soybean Oil Trial of cArdiovascular Risk

Start: Mar 2015Est. completion: Oct 201560 patients
N/ACompleted
NCT02024906Hamilton medicalsoy protein isolate

Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants

Start: Feb 2015Est. completion: Sep 20150
N/AWithdrawn

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

9 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 167,559 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.